Takeda Says 2nd Circ. Zanaflex Ruling Torpedoes Actos Row

By Eric Kroh (September 14, 2016, 5:29 PM EDT) -- Takeda told the Second Circuit on Tuesday that the panel's May ruling in a dispute over multiple sclerosis drug Zanaflex undermines a bid by buyers of the diabetes drug Actos to revive their case accusing Takeda of delaying generic competition for the drug through false patent descriptions....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!